Laboratoires DELBERT is Proud to Announce the Acquisition From Sanofi of TERALITHE 250 mg, Divisible Tablet and TERALITHE LP 400 mg, Prolonged-Release Tablet and Continues to Engage for Maintaining Access For Patients to MITM
Today, Laboratoires DELBERT is proud to announce the signature with Sanofi on March 31st, 2022 of the acquisition of Teralithe 250mg, divisible tablet and Teralithe LP 400mg, prolonged-release tablet (lithium carbonate) in France.
Laboratoires DELBERT (https://laboratoires-delbert.fr/) is a French Pharmaceutical company specialized in the « Revival of essential medications » : Marketing discontinuation, stock shortages …affect more and more essential medications especially in crisis periods with the consequence of narrowing the therapeutic arsenal of doctors that may force well-controlled patients to switch to other therapies.
With this acquisition Laboratoires DELBERT reinforces the execution of their strategy in order to ensure safe and continuous availability of Essential Medications to patients and reinforce their CNS portfolio.
“This acquisition demonstrates our ongoing commitment to invest in Major Therapeutical Interest Medications (MITM). Maintaining these medications available for patients in need is our priority,” said Marc Childs, & Thierry Hoffmann co-founders of Laboratoires DELBERT, « Laboratoires DELBERT built up over the time a portfolio of MITM that is anchored in 3 specific therapeutic areas : Antiinfectives, CNS and Oncology. »
Laboratoires DELBERT will reach over 30m€ sales by 2022 with double digit growth every year and already commercializes 14 products (out of which 13 princeps) for hospitals/specialists prescriptions.
Laboratoires DELBERT financed this acquisition thanks to very strong relationship with its financial partners who strongly believe in their values focused on patients access to MITM.
About Laboratoires DELBERT
Laboratoires DELBERT’ mission is to maintain Major Therapeutical Intererest Medication (MITM) and frequently used, available for patients.
Every year Laboratoires Delbert acquires new specialities with compromised future.
Laboratoires DELBERT focus their efforts on finding production facilities mainly across Europe.
With its collaborators and support from clinicians, galenicians, chemists Laboratoires DELBERT revive those medications and ensure their availability for clinicians and their patients in needs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005065/en/
Contact information
Press: Geneviève Cliquet Consultant – contact@cliquet-consultant.com
http://www.laboratoires-delbert.fr/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Momentum Recognized as a Clutch Global Honoree and Champion for Fall 20259.12.2025 18:09:00 EET | Press release
HTEC Momentum (formerly Momentum Design Lab), HTEC’s research, product design, management and innovation arm, has earned two of Clutch’s highest distinctions—Global Award honoree and Clutch Champion—reaffirming its ninth straight year as the platform’s top-rated UX agency worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209358771/en/ HTEC Momentum Recognized as a Clutch Global Honoree and Champion for Fall 2025 The Clutch Global Awards honorees are selected based on demonstrated industry expertise and exceptional delivery—evaluated through thousands of verified client reviews published on Clutch. Clutch’s rigorous, case-study-driven review process includes extensive verification to ensure the authenticity and depth of each submission. These distinctions further underscore HTEC Momentum’s position as a top-rated leader in UX strategy, design, and user research, reflecting the consistent satisfaction of our clients
Onego Bio Launches “ The Power of Trichoderma reesei ” Series to Showcase Innovation, Scale, and Real-World Applications9.12.2025 18:00:00 EET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein with precision fermentation*, today announced the launch of a new expert series titled “The Power of Trichoderma reesei: Building the Future with Fungi.” This multi-part initiative reveals the full potential of Trichoderma reesei, the microbial platform behind Onego’s Bioalbumen®, by spotlighting its scientific strengths, industrial scale, and practical performance across food manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209632524/en/ Headshot of Dr. Sharief Barends The first session, “Why Trichoderma reesei is Precision Fermentation’s Quiet Workhorse,” will be held on December 18, 2025, featuring Dr. Sharief Barends, Head of Research Leiden (Netherlands) and Head of Fungal Genetics at IFF, and Dr. Christopher Landowski, Co-Founder and Chief Technology Officer at Onego Bio. Together, they will explore the research legacy, strengths, and
Guinea Emerges as West Africa's New Digital Transformation Powerhouse9.12.2025 17:53:00 EET | Press release
The Republic of Guinea has reached a decisive turning point as a regional digital power. By hosting the Transform Africa Summit 2025, becoming the first francophone nation to receive this major continental event since its creation in 2013, Guinea confirmed the emergence of Conakry as a new digital innovation hub in West Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209780892/en/ Rose Pola Pricemou, Minister of Posts, Telecommunications and Digital Economy of the Republic of Guinea (Photo: AETOSWire) The numbers break all records: over 7,000 participants from 79 countries, including 47 ministers, 1,552 government representatives, 584 business leaders, over 590 start-ups, and 14 MoUs signed. Never before in the history of the Transform Africa Summit has such mobilisation been accomplished. This unprecedented turnout demonstrates international confidence in Guinea's ability to lead Africa's digital transformation ch
Rapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel Occlusions9.12.2025 17:47:00 EET | Press release
Rapid Medical™, a leading developer of active endovascular devices, announces the completion of patient enrollment in the DISTALS Trial, a multicenter randomized study assessing the TIGERTRIEVER 13™ device in patients with distal medium vessel occlusions (DMVO) in acute ischemic stroke. “DMVO strokes represent up to 40% of ischemic strokes and can cause significant disability, yet their treatment has remained uncertain. Recent neutral results from ESCAPE-MEVO and DISTAL made one thing clear: distal thrombectomy requires devices and trials specifically engineered for distal vessels,” said Dr. Jeffrey Saver of UCLA in California, Principal Investigator of DISTALS. “TIGER 13 and DISTALS bring that dedicated design. Completing enrollment is a major step toward evidence that can truly advance care for these patients.” The TIGER 13 is purpose-built for distal interventions. Its proprietary adjustable design is the only thrombectomy device that can actively remove tension from the vessel duri
Suzano Launches Nature Strategy and Reinforces the Strategic Importance of Biodiversity Conservation to the Business9.12.2025 17:41:00 EET | Press release
Suzano, the world’s largest pulp producer, has launched its Nature Strategy, reaffirming the company's commitment to biodiversity and how it guides decision-making within the business. Suzano's operations depend directly on nature, and the company recognizes that its longevity and ability to innovate are intrinsically linked to the health of ecosystems. Therefore, nature occupies a significant strategic role in the business’ vision. The science-led Nature Strategy, developed in collaboration with IUCN, is guided by the mitigation hierarchy: avoid, reduce, restore and transform. This approach enables the prevention of impacts, the minimization of risks, and the promotion of ecosystem regeneration. With support from IUCN, Suzano has pioneered the use of the STAR metric – a tool that enables the company to map sensitive areas within the territories where it operates, identify endangered species, and set priority actions required to reduce their risk of extinction. Biodiversity monitoring
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom